GALIG Gene Expression in Parkinson's Disease (GALIGPARK)

Centre Hospitalier Régional d'Orléans

Status: Completed

Conditions: Parkinson Disease

Treatments: Other: Blood sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT02923297

CHRO-2014-05

Details and patient eligibility

About

Parkinson's disease (PD) is the most frequent neurodegenerative disorder after Alzheimer's disease. It is characterized by motor symptoms (rigidity, tremor, slowness of movements), and non-motor symptoms (neuropsychological, psychiatric, pain ...). Neuronal death initiates in the brainstem and extends progressively through the entire cortex. The processes leading to cell death are poorly understood. Pathological cells exhibit abnormal deposits, called Lewy bodies, which contain numerous proteins. A major constituent of these protein deposits is alpha-synuclein. It has recently been demonstrated, in the Laboratory of Molecular Biophysics of the CNRS (Scientific Research National Center) in Orleans, that α-synuclein interacts with Cytogaligin, a protein produced by the proapoptotic GALIG gene. Cytogaligin could thus be a factor regulating α-synuclein activity or aggregation. It is postulated that the level of expression of the GALIG gene is different in Parkinson's disease patients compared with control subjects.

Enrollment: 37 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Parkinson's Disease according to the criteria of the UKPDBB (UK Parkinson's disease brain bank).

Exclusion criteria

• Insane patient arriving without a third party.
• Patient with Parkinson's disease arising from another etiology.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

37 participants in 1 patient group

Parkinson's disease patients

Other group

Description:

blood sampling

Treatment:

Other: Blood sampling